Phathom Pharmaceuticals (PHAT) CEO Steven Basta receives RSUs and stock options

Rhea-AI Filing Summary

Phathom Pharmaceuticals, Inc. reported an equity award transaction for its President, CEO and Director, Steven L. Basta. On January 2, 2026, he received 251,034 restricted stock units (RSUs) of common stock at a price of $0 per share, increasing his directly held common stock to 364,820 shares after the transaction. Each RSU represents a right to receive one share of common stock.

The RSUs vest over three years, with one-third of the award vesting on each of the first three anniversaries of January 2, 2026, subject to his continued service. On the same date, he was also granted a stock option to purchase 226,156 shares of common stock at an exercise price of $15.71 per share, expiring on January 1, 2036. One forty-eighth of the option vests monthly following the vesting commencement date, conditioned on his continuous service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Basta Steven L

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	226,156	$0.00	--
Grant/Award	Common Stock	251,034	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 221,156 shares (Direct); Common Stock — 364,820 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs") granted on January 2, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of January 2, 2026, the vesting commencement date (the "Vesting Commencement Date"), subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. 1/48th of the total number of shares of common stock subject to the option vest monthly following the Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Basta Steven L

(Last) (First) (Middle)

C/O PHATHOM PHARMACEUTICALS, INC.

100 CAMPUS DRIVE, SUITE 102

(Street)

FLORHAM PARK 07932

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Phathom Pharmaceuticals, Inc. [ PHAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		251,034(1)	A	$0	364,820	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.71	01/02/2026		A		226,156		(2)	01/01/2036	Common Stock	226,156	$0	221,156	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted on January 2, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of January 2, 2026, the vesting commencement date (the "Vesting Commencement Date"), subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

2. 1/48th of the total number of shares of common stock subject to the option vest monthly following the Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Steven L. Basta	01/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider equity awards did Phathom Pharmaceuticals (PHAT) report for Steven L. Basta?

Phathom Pharmaceuticals reported that President, CEO and Director Steven L. Basta received 251,034 RSUs of common stock and a stock option for 226,156 shares at an exercise price of $15.71 per share on January 2, 2026.

How do the RSUs granted to Steven L. Basta at Phathom Pharmaceuticals vest?

The 251,034 RSUs granted on January 2, 2026 vest in three equal installments. One-third vests on each of the first three anniversaries of the January 2, 2026 vesting commencement date, subject to his continued service.

What is the vesting schedule for Steven L. Basta’s stock option at Phathom Pharmaceuticals (PHAT)?

The stock option for 226,156 shares of common stock at an exercise price of $15.71 vests in 1/48th increments monthly following the vesting commencement date, provided Steven L. Basta maintains continuous service to the company, and expires on January 1, 2036.

How many Phathom Pharmaceuticals shares does Steven L. Basta own after the reported RSU transaction?

After the January 2, 2026 RSU grant, Steven L. Basta beneficially owns 364,820 shares of Phathom Pharmaceuticals common stock directly, as reported in the filing.

What type of SEC form was filed for Steven L. Basta’s Phathom Pharmaceuticals transactions?

The transactions were reported on an SEC Form 4, which discloses changes in the beneficial ownership of equity securities by officers, directors, and other insiders of Phathom Pharmaceuticals.

What role does Steven L. Basta hold at Phathom Pharmaceuticals (PHAT)?

Steven L. Basta is identified as a Director and an Officer of Phathom Pharmaceuticals, serving as President and CEO.